Correlation Between Vincerx Pharma and Oncotelic Therapeutics
Can any of the company-specific risk be diversified away by investing in both Vincerx Pharma and Oncotelic Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vincerx Pharma and Oncotelic Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Vincerx Pharma and Oncotelic Therapeutics, you can compare the effects of market volatilities on Vincerx Pharma and Oncotelic Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vincerx Pharma with a short position of Oncotelic Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vincerx Pharma and Oncotelic Therapeutics.
Diversification Opportunities for Vincerx Pharma and Oncotelic Therapeutics
0.84 | Correlation Coefficient |
Very poor diversification
The 3 months correlation between Vincerx and Oncotelic is 0.84. Overlapping area represents the amount of risk that can be diversified away by holding Vincerx Pharma and Oncotelic Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Oncotelic Therapeutics and Vincerx Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vincerx Pharma are associated (or correlated) with Oncotelic Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Oncotelic Therapeutics has no effect on the direction of Vincerx Pharma i.e., Vincerx Pharma and Oncotelic Therapeutics go up and down completely randomly.
Pair Corralation between Vincerx Pharma and Oncotelic Therapeutics
Given the investment horizon of 90 days Vincerx Pharma is expected to under-perform the Oncotelic Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Vincerx Pharma is 1.86 times less risky than Oncotelic Therapeutics. The stock trades about 0.0 of its potential returns per unit of risk. The Oncotelic Therapeutics is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest 3.00 in Oncotelic Therapeutics on August 31, 2024 and sell it today you would lose (0.80) from holding Oncotelic Therapeutics or give up 26.67% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Strong |
| Accuracy | 8.56% |
| Values | Daily Returns |
Vincerx Pharma vs. Oncotelic Therapeutics
Performance |
| Timeline |
| Vincerx Pharma |
| Oncotelic Therapeutics |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Vincerx Pharma and Oncotelic Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Vincerx Pharma and Oncotelic Therapeutics
The main advantage of trading using opposite Vincerx Pharma and Oncotelic Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vincerx Pharma position performs unexpectedly, Oncotelic Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncotelic Therapeutics will offset losses from the drop in Oncotelic Therapeutics' long position.| Vincerx Pharma vs. Cue Biopharma | Vincerx Pharma vs. Eliem Therapeutics | Vincerx Pharma vs. Inhibrx | Vincerx Pharma vs. Molecular Partners AG |
| Oncotelic Therapeutics vs. Processa Pharmaceuticals | Oncotelic Therapeutics vs. Advanced Proteome Therapeutics | Oncotelic Therapeutics vs. Cellectis SA | Oncotelic Therapeutics vs. ChitogenX |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Complementary Tools
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |